Vaccine immunotherapy for immune suppressed patients
A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naïve T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naïve T-cells and exposing the naïve T-cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T-cells to gain immunization of the T-cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions.
1 . A method for unblocking immunization at a regional lymph node by:
promoting differentiation and maturation of immature dendritic cells in a regional lymph node and;
allowing presentation by resulting mature dendritic cells of antigen to T-cells to gain immunization of the T-cells to the antigen.
2 . A method according to claim 1 , wherein said promoting step is further defined as administering a natural cytokine mixture (NCM) perilymphatically into lymphatics that drain into lymph nodes regional to a lesion to be treated.
3 . A method according to claim 2 , wherein the lesion is cancerous or an other persistent lesion.
4 . A method according to claim 3 , wherein the presented lesion is infectious.
5 . A method according to claim 1 , wherein the antigen is an endogenous antigen.
6 . A method according to claim 1 , wherein the antigen is an exogenous antigen.
7 . A method according to claim 2 wherein said administering step is further defined as injecting the NCM perilymphatically, intralymphatically, intranodally, intrasplenically, subcutaneously, intramuscularly or intracutaneously.
8 . A method of inducing immunization to cancer or persistent lesions by administering an effective amount of an exogenous antigen and an adjuvant consisting of a natural cytokine mixture (NCM).
9 . A method according to claim 7 , wherein said administering step is further defined as administering an NCM including IL-1, IL-2, IL-6, IL-8, γIFN and TNFα.
10 . A method according to claim 8 wherein said administering step is further defined as injecting the NCM perilymphatically, intralymphatically, intranodally, intrasplenically, subcutaneously, intramuscularly or intracutaneously.
11 . A method for overcoming mild to moderate T cell depletion and restoring T cell immune response by inducing production of naïve T cells.
12 . A method according to claim 11 , wherein said inducing step is further defined as administering a natural cytokine mixture (NCM).
13 . A method according to claim 11 wherein said administering step is further defined as injecting the NCM perilymphatically, intralymphatically, intranodally, intrasplenically, subcutaneously, intramuscularly or intracutaneously.
14 . A method according to claim 12 , wherein said administering step is further defined as injecting an NCM including IL-1, IL-2, IL-6, IL-8, γIFN and TNFα.
15 . A method according to claim 14 , wherein said administering step including administering about 150-600 units of IL-2 per injection in the NCM.
16 . A method according to claim 11 , wherein said blocking and inducing steps are further defined as codelivering cyclophosphamide and a nonsteroidal anti-inflammatory drug (NSAID).
17 . A method of treating a cancer or other persistent lesion in an immune suppressed patient by administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exongenously administering antigen from the cancer or persistent lesion.
18 . A method according to claim 14 , wherein said administering step is further defined as injecting an NCM including IL-1, IL-2, IL-6, IL-8, TNFα and γIFN.
19 . A method according to claim 18 , wherein said administering step is further defined as injecting an NCM including IL-1, IL-2, IL-6; IL-8, TNFα and γIFN.
20 . A method according to claim 17 , further including the steps blocking endogenous suppression of T-cells directly or indirectly by the endogenous lesion being treated.
21 . A method according to claim 17 , wherein said blocking and inducing steps are further defined as codelivering cyclophosphamide and a nonsteroidal anti-inflammatory drug (NSAID).
22 . A method according to claim 21 , wherein the NSAIDS is selected from the group including indomethacin, ibuprofen, vioxx, celebrex and other related compounds.
23 . A method of vaccine immunotherapy including the steps of:
inducing production of naïve T-cells and
exposing the naïve T-cells to endogenous or exogenous antigens.
24 . A method according to claim 23 , wherein said exposing step is further defined as exposing the naïve T-cells to endogenously processed peptide preparation resident in regional nodes of a patient who possesses a lesion.
25 . A method according to claim 24 , wherein the lesion is cancerous or infectious.
26 . A method according to claim 23 , wherein said exposing step is further defined as administering an exogenously produced antigen.
27 . A method according to claim 23 , wherein said antigen is otherwise non-immunogenic peptide.
28 . A method according to claim 23 , wherein said exposing step is further defined as immunizing the naïve T-cells with matured peptide presenting dendritic cells at a lymph node distal from a lesion to be treated.
29 . A method of treating lymphocytopenia by administering an effective amount of a natural cytokine mixture.
30 . A method of vaccine immunotherapy including the steps of:
promoting differentiation and maturation of immature dendritic cells in a lymph node;
allowing presentation by resulting mature dendritic cells of antigen to T cells to gain immunization of the T cells to the antigen; and
preventing development of metastasis.
31 . A method of vaccine immunotherapy including the steps of:
unblocking immunization at a lymph node and then generating systemic immunity.
32 . The method as set forth in claim 31 further including the step of preventing development of metastasis.
33 . A method of preventing development of metastasis by unblocking immunization at a lymph node regional to a lesion, wherein the lesion is capable of metastasizing.
34 . A method of unblocking immunization at a lymph node by:
selecting conditions in a patient known to be associated with sinus histocytosis and hypoplasia of a lymph node; promoting differentiation and maturation of immature dendritic cells in the lymph node; and allowing presentation by resulting mature dendritic cells of antigen to T cells to gain immunization of the T cells to the antigen.
35 . A method of treating cancer or other persistent lesion in an immune suppressed patient by:
selecting conditions in a patient known to be associated with sinus histocytosis and hypoplasia of a lymph node; promoting differentiation and maturation of immature dendritic cells in the lymph node; and allowing presentation by resulting mature dendritic cells of antigen to T cells to gain immunization of the T cells to the antigen.
36 . A method of treating an immune suppressed patient by:
selecting conditions in a patient known to be associated with sinus histocytosis and hypoplasia of a lymph node; promoting differentiation and maturation of immature dendritic cells in the lymph node; and allowing presentation by resulting mature dendritic cells of antigen to T cells to gain immunization of the T cells to the antigen.
37 . A method of restoring function of a damaged immune system by:
first identifying immune incompetence at at least one lymph node; promoting differentiation and maturation of immature dendritic cells in the lymph node; and allowing presentation by resulting mature dendritic cells of antigen to T cells to gain immunization of the T cells to the antigen.
38 . A method of unblocking immunization at a regional lymph node by:
selecting conditions in a patient known to be associated with sinus histocytosis and hypoplasia of a lymph node;
promoting differentiation and maturation of immature dendritic cells in a regional lymph node, by administering an effective amount of an exogenous antigen and an immune response enhancing agent; and
allowing presentation by resulting mature dendritic cells of antigen to T cells to gain immunization of the T cells to the antigen.
39 . A method of inducing maturation of dendritic cells by:
selecting conditions in a patient known to be associated with sinus histocytosis and hypoplasia of a lymph node;
promoting differentiation and maturation of immature dendritic cells in the lymph nodes; and
allowing presentation by resulting mature dendritic cells of antigens to T cells to gain immunization of the T cells to the antigen.
40 . A kit for use in conjunction with cancer therapy, comprising:
a test for selecting conditions in a patient known to be associated with sinus histocytosis and hypoplasia of a lymph node; and
an injectable composition for promoting differentiation and maturation of immature dendritic cells in the lymph node.
41 . A kit for use in treating immune incompetence, comprising:
a test for selecting conditions in a patient known to be associated with sinus histocytosis and hypoblasion of a lymph node; and
an injectable composition for promoting differentiation and maturation of immature dendritic cells in the lymph node.
42 . A kit for use in conjunction with cancer therapy comprising an injectable composition to prevent metastasis of a cancer.
43 . A kit for use in conjunction with preventing metastasis comprising a composition for unblocking immunization at a lymph node regional to a lesion, wherein the lesion is capable of metastasis.
44 . A kit for delaying and preventing the recurrence of an otherwise ablated tumor comprising an injectable composition for promoting differentiation and maturation of immature dendritic cells in a lymph node.
45 . A method of delaying recurrence of metastasis by promoting differentiation and maturation of immature dendritic cells in a regional lymph node by administering an effective amount of an exogenous antigen and an immune response enhancing agent; and allowing presentation by resulting mature dendritic cells of antigen to T cells to gain immunization of the T cells to the antigen.
46 . A composition for increasing CD 45RA positive T cells comprising a natural cytokine mixture (NCM) plus a low dosage of cyclophosphamide, indomethacin, and zinc.
47 . The composition as set forth in claim 46 , wherein said NCM includes IL-1, IL-2, IL-6, IL-8, γIFN, and TNFα.
48 . The composition as set forth in claim 47 , wherein said IL-2 is about 120-600 units of IL-2 per injection in the NCM.
49 . The composition as set forth in claim 48 , wherein said IL-2 is about 120-340 units of IL-2 per injection in the NCM.
50 . The composition as set forth in claim 46 , further comprising a nonsteroidal anti-inflammatory drug (NSAID).
51 . A formulation for inhibiting metastasis comprising 150-600 units of IL-2.
52 . A method of immunizing patients to unidentified tumor antigens at the lymph node level by administering a natural cytokine mixture.